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Abstract 
A live attenuated Salmonella Enteritidis (SE) capable of constitutively secreting detoxified double mutant Escherichia 
coli heat labile toxin (dmLT) was developed. The biologically adjuvanted strain was generated via transformation of a 
highly immunogenic SE JOL1087 with a plasmid encoding dmLT gene cassette; the resultant strain was designated 
JOL1641. A balanced-lethal host-vector system stably maintained the plasmid via auxotrophic host complementa-
tion with a plasmid encoded aspartate semialdehyde dehydrogenase (asd) gene. Characterization by western blot 
assay revealed the dmLT subunit proteins in culture supernatants of JOL1641. For the investigation of adjuvanticity 
and protective efficacy, chickens were immunized via oral or intramuscular routes with PBS, JOL1087 and JOL1641. 
Birds immunized with JOL1641 showed significant (P ≤ 0.05) increases in intestinal SIgA production at the 1st and 
2nd weeks post-immunization via oral and intramuscular routes, respectively. Interestingly, while both strains showed 
significant splenic protection via intramuscular immunization, JOL1641 outperformed JOL1087 upon oral immuniza-
tion. Oral immunization of birds with JOL1641 significantly reduced splenic bacterial counts. The reduction in bacterial 
counts may be correlated with an adjuvant effect of dmLT that increases SIgA secretion in the intestines of immu-
nized birds. The inclusion of detoxified dmLT in the strain did not cause adverse reactions to birds, nor did it extend 
the period of bacterial fecal shedding. In conclusion, we report here that dmLT could be biologically incorporated 
in the secretion system of a live attenuated Salmonella-based vaccine, and that this construction is safe and could 
enhance mucosal immunity, and protect immunized birds against wild-type challenge.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Salmonella enterica serovar Enteritidis is one of the 
most frequently isolated bacteria from human infections 
worldwide [1]. Foodborne salmonellosis is widespread in 
developing and developed countries, resulting in approxi-
mated 155 000 deaths every year [2]. Eggs, meat and meat 
products are the most common transmission vehicles of 
Salmonella infections [3]. Due to the ubiquitous pres-
ence and rapid spread of Salmonellae in poultry prem-
ises, enforcing control measures can be expensive and 
still does not ensure complete elimination of the organ-
ism. Control strategies, such as culling, antibiotic inter-
ventions, and Salmonella-free feed approaches, are being 
deployed with varying success to control the Salmonella 
transmission cycle [4]. In particular, poultry vaccination 
is the suggested ideal strategy for controlling Salmo-
nella Enteritidis infections on poultry farms and thereby 
reducing food contamination [5, 6].
The heat-labile enterotoxin (LT) of E. coli is a potent 
oral adjuvant boosting both the humoral and cellular 
immune responses when co-administered with anti-
gens. However, it also induces secretory diarrhea, even 
at low doses [7, 8]. It is composed of a monomeric A 
subunit and pentameric B subunits [9]. The usefulness 
of native LT as an adjuvant is eclipsed by its toxicity. 
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Amino acid substitutions have been introduced into the 
native LT to generate active but non-toxic mutant pro-
tein adjuvants. The first such example was the mutant 
labile toxin, mLT or LT(R192G), in which the amino 
acid glycine was substituted for arginine in the A-sub-
unit, thereby preventing enzymatic cleavage [10]. mLT 
showed reduced toxicity [11] and maintained adjuvan-
ticity in  vitro and in animal studies, inducing a bal-
anced Th1/Th2 cytokine and antibody subclass profile 
equivalent to native LT [12–14]. However, at a higher 
dosage (100  µg of mLT), human subjects showed mild 
to moderate diarrhea [15]. To alleviate this problem, an 
additional mutation was added to further detoxify the 
toxin and thus generate the double mutant, LT (R192G/
L211A), or dmLT [16]. Detoxified dmLT has reduced 
cyclic AMP activation and exhibited no enterotoxicity, 
but most importantly, it retained the ability to func-
tion as an oral mucosal adjuvant. LT and its variants 
can enhance immune responses to whole cell vaccines 
against enterotoxigenic E. coli,  Streptococcus pneumo-
nia and Helicobacter pylori  in different mouse models 
[17, 18].
Several studies have utilized conjugation of purified 
recombinant dmLT protein with candidate antigens for 
immunological studies, dose optimizations, and vaccine 
development [10, 19, 20]. However, based on our previ-
ous studies with adjuvanted vaccine strains, we perceived 
that the use of strains inherently secreting [21] or dis-
playing [22] adjuvant molecules would be more practi-
cal for bulk production and may be more convenient for 
field deployments. In this study, to improve the vaccine-
biological adjuvant system and to surpass the multistep 
processing of dmLT-conjugations, we investigated the 
use of a highly immunogenic live attenuated SE strain 
that secretes dmLT adjuvant molecules constitutively as 
a vaccine candidate. The protective efficacy against viru-
lent challenge, immune responses, and safety as a vaccine 
candidate, were assessed in a chicken model.
Materials and methods
Experimental birds, bacterial strains and plasmids
Male white leghorn chickens were used to examine 
the protective efficacy, induction of immune response, 
and safety. All experimental work involving birds was 
approved (CBU 2014-1-0038) by the Chonbuk National 
University Animal Ethics Committee, in accordance 
with the guidelines of the Korean Council on Animal 
Care. The bacterial strains, plasmids, and primers used 
are listed in Table  1. All E. coli and Salmonella Enter-
itidis strains were grown in Luria–Bertani (LB) broth. 
For bacterial counting, Salmonella strains were grown on 
brilliant green agar (BGA) at 37  °C, for enrichment and 
recovery they were grown in Rappaport–Vassiliadis broth 
at 42 °C. Fifty µg/mL of diaminopimelic acid supplement 
was added to media for growing asd gene-deleted strains.
Construction of plasmids harboring dmLT
The codon-optimized dmLT gene incorporating the 
desired nucleotide mutations was chemically synthesized 
(Bioneer, South Korea). It consisted of the open reading 
frame (ORF) of the LTA subunit and an overlapping ORF 
of the LTB subunit (Figure  1). The desired amino acid 
substitutions in the LTA subunit were glycine instead of 
arginine and alanine instead of leucine at positions 192 
and 211, respectively [16]. The synthesized gene cassette 
was enzymatically released via the incorporated EcoRI 
and HindIII restriction sites. The released fragment was 
then cloned into the based vector pJHL65. The con-
structed plasmid consisted of the cloned asd gene that 
assisted plasmid-host complementation, the dmLT cas-
sette fused with a bla secretion signal and a 6xHis tag 
sequence. The fused cassette was constitutively expressed 
under the Ptrc promoter. The plasmid was then used to 
transform JOL1084 (ΔlonΔcpxrΔasd) via electroporation. 
The resulting strain was designated JOL1641 (Table  1). 
For comparative studies, JOL1084 was transformed with 
asd + pMMP65 without the dmLT cassette.
Immunoblot confirmation of dmLT expression in culture 
supernatants
dmLT subunit expression was confirmed from the cul-
ture supernatant of JOL1641 using a previously described 
protocol with minor modifications [21]. Briefly, 200-mL 
supernatants from broth cultures grown at 37 °C (OD600 
0.8) were recovered following centrifugation at 3380  g 
for 15 min. The supernatant containing the secreted pro-
tein was filtered through a 0.22-µm pore-size filter and 
Table 1 Bacterial strains and plasmids used in this study
Strain/plasmid Description Reference
Salmonella Enteritidis
 JOL1182 Wild type isolate from chicken, challenge 
strain
Lab stock
 JOL860 Wild type isolate from chicken for antigen 
preparations
Lab stock
 JOL1087 ΔlonΔcpxRΔasd, used as base vaccine 
strain
[21]
 JOL1641 JOL1087 containing pJHL65-dmLT This study
Plasmids
 pJHL65 asd + vector, pBR ori, b-lactamase signal 
sequence-based periplasmic secretion 
plasmid, 6xHis, high copy number
[34]
 pJHL65-dmLT pJHL65 containing dmLT constitutively 
express under Ptrc promoter, secreted 
under bla secretory system
This study
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precipitated with chilled 20% trichloroacetic acid over-
night. The precipitated proteins were pelleted at 30 000 g 
for 20 min, washed with acetone and resuspended in PBS. 
After heating at 96 °C for 5 min, the proteins were sepa-
rated using 15 and 18% SDS-PAGE gels for LTA and LTB, 
respectively. The separated proteins were blot transferred 
to polyvinylidene fluoride (PVDF) membranes (Millipore, 
USA) and overnight blocking was performed in 5% skim 
milk. The LTA subunit was detected via the incorporated 
histidine tags, using primary mouse IgG1 anti-His-tag 
(Penta-His™, Life Technologies, Eugene, OR, USA) and 
secondary anti-mouse IgG1 antibody-HRPO conjugate 
(Sigma-Aldrich, USA) antibodies. The LTB subunit was 
detected using a lab-generated hyperimmune serum pri-
mary antibody (rabbit anti-LTB) and a secondary anti-
rabbit IgG antibody-HRPO conjugate (Sigma-Aldrich). 
Reactive bands were developed using the West-One™ 
Western Blot Detection System (iNTRON, KOR) and 
bands were visualized using a KODAK Image Station 
(Kodak, New Haven, CT, USA).
GM1 ganglioside binding assay
GM1 based functional assay was conducted to validate 
the presence of dmLT in culture supernatants. GM1-
based sandwich ELISA was performed based on a previ-
ously reported protocol with minor modifications [22]. 
The modifications were application of dmLT protein and 
use of anti-LTA antibody. Briefly, 5  µg/mL of purified 
ganglioside GM1 from bovine brain (Santa Cruz Biotech-
nology, USA) was used for coating the ELISA plate, and 
the remaining binding sites were blocked by incubating 
the plates with 200 μL of 5% skimmed milk. After wash-
ing three times with PBST, precipitated supernatants of 
JOL1640 was added and incubated at 37 °C for 2 h. The 
unbound sites were blocked with 200 μL of 5% skimmed 
milk. A 1:5000 dilution of anti-LTA rabbit serum was 
added to the wells and then incubated at 37  °C for 1  h. 
After washing five times with PBST, the plates were incu-
bated with a 1:10 000 dilution of HRP-conjugated goat 
anti-rabbit IgG secondary antibody. The activity of bound 
HRP was measured using OPD (Sigma-Aldrich, St. Louis, 
MO, USA). A negative binding control involving all the 
steps was also carried out in parallel, except that GM1 
coating was replaced with 5% skimmed milk.
Immunization and challenge of chickens
Fifty white leghorn chickens were divided equally into 
five groups (n = 10) and were immunized orally or intra-
muscularly with PBS (non-immunized control), JOL1087 
(parental strain) and JOL1641 (SE-dmLT). All chickens 
were immunized at 4  weeks of age. The immunization 
regime consisted of 1 × 108 cells in 200 µL PBS for the oral 
route and 1 × 107 cells in 200 µL PBS for the intramus-
cular route (Table 2). The birds were then simultaneously 
utilized for safety assessment, immunological and pro-
tective efficacy studies. All bird groups were challenged 
during the 5th week post-vaccination with 1 ×  109  CFU 
in 200  µL using a virulent Salmonella Enteritidis strain 
(JOL1182) administered via the oral route.
Safety and fecal shedding of vaccine strains
The safety qualities of the strains were investigated 
through regular monitoring of the birds until euthani-
zation. The investigated parameters included anorexia, 
depression, and diarrhea. The presence of the vac-
cine strains in fecal samples was monitored 3, 7, 14 and 
21  days post-immunization. Fecal samples were pro-
cessed using a protocol described in detail elsewhere 
[21]. Birds were kept in clean disinfected buckets prior 
to fecal sampling. The fecal samples were collected and 
resuspended at a ratio of 1:10 in buffered peptone water. 
After brief pelleting, various dilutions of the supernatant 
were plated directly on BGA plates. Simultaneously, 1 mL 
of the supernatant was also enriched in 4 mL RV broth 
Figure 1 Components of pJHL65-dmLT. The SE asd + plasmid 
with ori pBR (pJHL65) harboring a constitutive expression system 
under which the dmLT cassette was expressed along with a fused bla 
secretion signal sequence. Lower case DNA sequence (inside the box) 
depicts codon substitution and corresponding non-synonymous 
amino acid substitutions, R192G and L211A.
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and incubated 48  h at 42  °C. A loop of the enrichment 
broth was streaked onto BGA and incubated at 37 °C for 
16 h. Salmonella-like colonies that appeared after plating 
or streaking on BGA were further confirmed using SE-
specific [23] and candidate strains specific primers.
Protective efficacy and bacterial recovery from infected 
organs
To evaluate the protective efficacy of the SE-dmLT 
strains, immunized birds were challenged with the SE 
virulent strain JOL1182 as described above. The protec-
tive efficacy of the dmLT-secreting strain JOL1641 was 
compared with those of the non-immunized control 
and the parental strain JOL1087. The birds were classi-
fied into Groups A, B and C corresponding to inoculation 
with PBS only and strains JOL1087 and JOL1641 respec-
tively. The challenge experiment was carried out accord-
ing to the protocol described previously with minor 
modifications [21]. At days 7 and 14 post-challenge, the 
birds were euthanized, and organ bacterial recovery and 
post-mortem examination were performed. To determine 
bacterial loads, samples of the liver, spleen, and cecum 
were weighed and then homogenized in 2  mL buffered 
peptone water. Hundred µL of the homogenate sample 
was plated on BGA for direct culture. The resulting colo-
nies were counted after incubation at 37  °C for 16 h. In 
parallel, the remaining 1 mL homogenate was enriched in 
4 mL of RV broth and incubated 48 h at 42 °C. A loop of 
the enrichment broth was streaked onto BGA and incu-
bated at 37  °C for 16  h. Salmonella-like colonies were 
further confirmed using specific PCR primers. The num-
ber of bacterial colonies obtained via direct culturing 
were determined and expressed as the mean log10 CFU/g 
of samples. For the purposes of statistical analysis, a 
sample that was positive only after enrichment was rated 
as log10 =  1.0. A sample that was negative after enrich-
ment was assigned as log10 = 0 [24].
Assessment of systemic and mucosal humoral immune 
responses
To measure anti-SE-specific antibodies, blood, and intes-
tinal lavage samples were collected at weekly intervals 
for 5  weeks post-immunization. Heparinized peripheral 
blood was used to recover plasma samples to determine 
systemic immunoglobulin G (IgG) concentrations. Intes-
tinal lavage samples were collected to determine secretory 
IgA (SIgA) concentrations, as per the protocol described 
elsewhere [25]. Indirect ELISA was performed for IgG 
and SIgA with an outer membrane protein (OMP) frac-
tion extracted from wild-type JOL860, following a previ-
ously described protocol with minor modifications [26]. 
Changes included 40  min centrifugation at 20 000  g of 
sonicated pellet and final harvesting at 130 000 g for 1 h 
at 4  °C. IgG and SIgA samples were diluted with PBS at 
ratios of 1:100 and 1:10, respectively. Each sample was 
tested in duplicate, and the mean OD492 was calculated for 
each time point and compared to that of control samples.
Statistical analysis
Statistical analyses were applied wherever applicable. 
Analysis of variance (ANOVA) was used to analyze the 
differences among the group means; Tukey’s HSD post 
hoc analysis was further used to differentiate within 
groups. Differences were considered statistically signifi-
cant at a P value of ≤0.05. In order to achieve a better 
statistical fit, bacterial enumeration log counts “x” at day 
14 post-challenge (orally immunized groups) were math-
ematically transformed using the equation y = (x + 1).
Results
Construction and validation of dmLT
The synthesized dmLT cassette containing suitable 
nucleotide mutations was successfully cloned inside the 
backbone vector pJHL65 (Figure 1). The expression and 
secretion of dmLT in JOL1641 were validated using pre-
cipitated secretory protein harvested from a JOL1641cul-
ture. dmLT subunit A and subunit B were detected by 
using anti-His tag antibody and anti-LTB polyclonal anti-
body, respectively. The total size of LTA (29  kDa) fused 
with 6xHis and a signal peptide (3  kDa) was approxi-
mately 32 kDa. The expected band sizes of 32 and 12 kDa 
corresponding to monomeric A and B subunits, respec-
tively, were observed on the western blots (Figure 2). Hol-
otoxin formation was confirmed based on LTB binding 
to GM1 ganglioside receptor. Mean OD  ±  SEM values 
of 0.3608 ±  0.0117 and 0.1353 ±  0.0078 were observed 
for GM1-dmLT and non-GM1-dmLT wells. Minimal 
Table 2 Immunization of  hens with  the Salmonella Enter-
itidis strains and challenge
a Dose for immunization expressed as number of Salmonella Enteritidis 
cells/200 µL of PBS.
b Chickens were challenged at the 9th week of age via oral route. Chickens were 






A PBS control Oral 200 µL  
sterile PBS
JOL1182
1 × 109 
cells/200 µL 
PBS
B JOL1087 Oral 1 × 108
Intramuscular 1 × 107
C JOL1641 Oral 1 × 108
Intramuscular 1 × 107
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OD was observed with GM1 negative wells due to the 
absence of toxin-receptor complex. Hence, no or mini-
mal primary and conjugated-secondary antibodies were 
available for generating colour reaction.
Safety and fecal bacterial shedding
No adverse effects on the general health conditions of the 
immunized birds were observed. Native heat labile toxin 
has the tendency to evoke severe diarrhea; however, with 
the suitable mutations in the LTA subunit, JOL1641 did 
not induce diarrhea among the immunized birds. Fur-
thermore, upon postmortem examination, no conspicu-
ous pathological lesions, such as organ enlargement, 
infarctions or necroses, were observed. The expression 
of detoxified toxin in JOL1641 did not prolong fecal 
shedding in the birds. The shedding pattern of JOL1641-
immunized birds in Group C was comparable to that of 
Group B JOL1087-immunized birds (Table 3).
Systemic and mucosal humoral immune responses
The systemic and mucosal humoral immune responses 
elicited by JOL1641 were investigated by measuring the 
levels of plasma IgG and intestinal lavage SIgA from 
samples obtained from immunized and non-immunized 
chickens. All immunized birds elicited strong antibody 
production against the SE specific outer-membrane pro-
tein antigens. Bird groups immunized via the oral route 
showed a significant (P ≤ 0.05) rise in IgG antibody titers 
as early as the second week post-immunization, com-
pared to the non-immunized group (Figure 3A). Group B 
birds showed a declining level of IgG beyond the 4th week 
post-immunization while Group C birds showed sig-
nificantly (P ≤ 0.05) higher levels of IgG at the 5th week 
post-immunization. Bird groups immunized via the intra-
muscular route showed significant increases in IgG levels 
from the first week post-immunization as compared to 
the control group (Figure 3B). SE-dmLT adjuvant inocu-
lated birds (Group C) showed an abrupt rise in IgG lev-
els by the 2nd week, which gradually decreased towards 
the 5th week post-immunization; the observed levels were 
significantly higher than those of Groups A and B. To 
evaluate the role of SE-dmLT in inducing mucosal immu-
nity, the levels of intestinal SIgA were measured. The 
SIgA levels of orally immunized birds showed significant 
differences as compared to control non-immunized birds 
(P ≤ 0.05). At the first and 2nd week post oral immuniza-
tion, the SIgA levels were relatively similar between the 
groups; by the second week, Group C birds showed sig-
nificant differences in SIgA levels as compared to Group 
B birds (Figure 4A). Interestingly, Group C birds had sig-
nificantly (P ≤ 0.05) higher concentrations of SIgA at all 
sampling time points compared to Groups A and B post 
intramuscular immunization (Figure 4B). 
Figure 2 Western blot validation of dmLT from JOL1641. Lane 
M, prestained protein marker; lane 1, supernatant from the blank 
vector control; lane 2, JOL1641. A Immunoblot analysis of the LTA 
subunit, black arrow head poinitng the ~32-kDa reactive protein 
band. B Immunoblot analysis of the LTB subunit, white arrow head 
indicating the ~12-kDa reactive protein band.
Table 3 Faecal shedding of constructed strains post immunization
a Number of birds positive for faecal shedding/number of birds screened.
Group Constructed strain Route Day
3 7 14 21
A PBS control Oral 0/6a 0/6 0/6 0/6
B JOL1087 Oral 4/6 3/6 0/6 0/6
Intramuscular 2/6 0/6 0/6 0/6
C JOL1641 Oral 4/6 2/6 0/6 0/6
Intramuscular 0/6 0/6 0/6 0/6
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Challenge and protection study
The protective efficacy of the strain was investigated by 
immunizing 4-week-old birds. The immunized birds 
were challenged with wild-type JOL1182 in the 5th week 
post-immunization. Birds were euthanized on days 7 and 
14 post-challenge, the gross appearance of postmortem 
organs was examined and the wild type bacterial load 
was counted in selected organs including, liver, spleen, 
and cecum. Apart from mild splenomegaly, no severe 
pathological lesions were observed in the internal organs 
of the immunized birds. On the 7th day post-challenge, 
birds immunized orally did not show signs of having sig-
nificantly cleared the infection from their livers any faster 
than the control non-immunized birds (Figure 5A). The 
splenic bacterial loads were significantly lower in Group 
C birds (P  ≤  0.05). On the 7th day post-challenge, bird 
groups immunized via the intramuscular route showed 
significantly lower bacterial loads compared to control 
birds (P ≤ 0.05; Figure 5B). The splenic bacterial counts 
were significantly lower in both Group B and C birds 
(P ≤  0.05). The cecal bacterial counts were significantly 
lower in Group C birds (P ≤  0.01) compared to Group 
A and B birds. On the 14th day post-challenge, splenic 
and caecal counts were significantly lower in bird groups 
immunized orally (P ≤ 0.05; Figure 5C). On day 14 post-
challenge, the log bacterial counts were reduced among 
Figure 3 Relative plasma IgG levels in immunized birds. 
IgG antibodies produced against the SE outer membrane protein 
antigens were measured using indirect ELISA. Bird groups were 
inoculated with: A, PBS control; B, JOL1087 and C, JOL1641. A Groups 
inoculated via the oral route. Immunized birds showed significant 
differences in their IgG levels as compared to the control group. This 
significant difference was observed at the 2nd week post-immu-
nization. B Groups inoculated via the intramuscular route. Birds in 
Group C showed prominent increase in the IgG levels that declined 
gradually. As compared to the non-immunized group, the immunized 
groups showed significant differences at all sampling time points, 
except during the first week. *Significant difference compared to the 
control group (P ≤ 0.05), **Significant difference between immunized 
groups (P ≤ 0.05).
Figure 4 Relative intestinal SIgA levels in immunized birds. 
SIgA antibodies produced against the SE outer membrane protein 
antigens were measured using indirect ELISA. Bird groups were inoc-
ulated with: A, PBS control; B, JOL1087 and C, JOL1641. A Bird groups 
immunized via oral route. At the second week post-immunization, 
Group C birds showed significant rises in SIgA levels as compared 
to the other groups. B Bird groups immunized via the intramuscular 
route. At the first week post-immunization, Group C birds showed 
significant increases in SIgA. Birds in Group C showed consistent 
increases in SIgA levels 2, 3 and 4 weeks post-immunization. *Signifi-
cant difference compared to the other groups (P ≤ 0.05).
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the bird groups immunized intramuscularly, compared 
to the non-immunized group of birds (Figure 5D). Of the 
ten birds in both Groups B and C, four were found to be 
negative for the SE challenge strain, while all ten birds in 
the Group A control group were found to be positive.
Discussion
Upon infection via the oral route, Salmonella spreads 
rapidly, crossing the intestinal mucosa and invading the 
spleen and liver. The ability of Salmonella to evade kill-
ing by phagocytic cells and its pan tropism towards a 
variety of non-phagocytic cells leads to massive bacte-
rial replication, resulting in high bacterial loads and sys-
temic Salmonella infection [27]. It would be pragmatic 
to halt the invading Salmonella organisms before they 
penetrate their replication niche. Essentially, SIgA anti-
bodies present in the intestinal mucus act as an impor-
tant immunological barrier, preventing adherence and 
subsequent invasion of the intestinal lining by Salmo-
nella. The present study investigated the effectiveness of 
the complete molecule of detoxified E. coli labile toxin 
dmLT in enhancing immunity against wild type Salmo-
nella Enteritidis infection. The double mutant labile toxin 
gene was fused with the bla secretion signal sequence 
and was expressed under the constitutive promoter Ptrc. 
Furthermore, the stability of the plasmid was maintained 
by host-plasmid complementation using the asd gene. 
Salmonella asd gene knock-out strains transformed with 
this plasmid were stable and constitutively produced 
dmLT proteins, which are directed to the bacterial peri-
plasmic space and then secreted. In order to achieve a 
strong protective ability and immunogenic properties, 
the dmLT adjuvanted strain JOL1641 was developed 
based on the highly immunogenic lon and cprxR gene-
deleted SE strain (JOL1087). Deletion of lon and cprxR 
renders the organism attenuated by impairing intracel-
lular replication while increasing its immunogenicity 
by up-regulating adhesion and invasion [28–30]. These 
properties of JOL1087 added additional suitable quali-
ties to the vaccine candidate as evidenced by plasma IgG 
Figure 5 Recovery of challenge strain from internal organs of chickens. Enumeration of wild type bacterial load was performed in liver, 
spleen, and cecum of the bird after virulent wild type challenge. (A) Log10 organ bacterial counts of bird groups immunized orally, at the 7th day 
post-challenge. Spleens from Group C showed significant reduction in challenge bacterial load as compared to Group A and B (P ≤ 0.05) birds. (B) 
Log10 organ bacterial counts of bird groups immunized intramuscularly, at the 7th day post-challenge. The splenic bacterial loads were significantly 
lower in Group B and C as compared to Group A (P ≤ 0.05). The caecal bacterial load was significantly lower in Group C, birds immunized with 
adjuvanted strain (P ≤ 0.05). (C) Log10 organ bacterial counts of bird groups immunized orally, at the 14th day post-challenge. Spleens and ceca of 
Group B and C showed significant decreased in bacterial loads as compared to the control group A (P ≤ 0.05). (D) Log10 organ bacterial counts of 
bird groups immunized intramuscularly, at the 14th day post-challenge. In Group B and C, the number of birds determined to be completely nega-
tive of the challenge strain were 4 of 10.
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levels (Figure  3), intestinal lavage SIgA antibody levels 
(Figure 4) and protection (Figure 5).
Expression of dmLT was confirmed by immunoblot 
assay, which revealed the presence of the LTA and LTB 
proteins in the secretions of JOL1641 (Figure  2). As 
reported earlier, the double mutations in the gene for E. 
coli labile toxin eLT resulted in inhibition of proteolytic 
cleavage of LT-A into A1 and A2. It exhibited reduced 
enzymatic activity and no detectable toxicity either 
in vitro or in vivo [16]. Our observations confirmed that 
the incorporation of dmLT in the strain did not cause 
any additional undesirable effects, like general illness, 
diarrhea or prolonged fecal shedding (Table 3). In addi-
tion, no immunization-induced pathological lesions 
were observed in the internal organs upon postmortem 
examination.
Native toxins such as cholera and labile toxins and 
their variant toxoids can enhance both humoral and cell-
mediated immunity [17, 31, 32]. Humoral immunity plays 
an important role in the early stages of infection, during 
which extracellular Salmonella Enteritidis is opsonized 
by antibodies, thereby preventing cell penetration [33]. 
Systemic antibodies opsonize Salmonella Enteritidis and 
thus enhance receptor-mediated uptake by macrophages. 
Our data revealed that the candidate strain was highly 
immunogenic when administered either orally or intra-
muscularly. The strain was capable of inducing strong 
anti-Salmonella specific systemic IgG, and the levels 
were significantly different from those of control birds. 
We observed a significant induction effect of mucosal 
adjuvant on intestinal SIgA production by the 2nd week 
post-immunization upon oral administration among 
Group C birds (Figure  4A). Interestingly, SIgA produc-
tion in the intestinal lavages was significantly higher 
during the 1st week post-immunization via the intramus-
cular route among Group C birds; this significant rise 
was observed 1 week earlier compared to the oral route 
of immunization. Overall, our data indicated that oral 
and intramuscular administration of SE-dmLT resulted 
in a significant elevation of SIgA production, compared 
to the non-adjuvanted SE strain.
Salmonella live attenuated vaccines are known to 
induce a strong immune response [6]. In order to deter-
mine the effects of the vaccines in the early stages of 
infection, enumeration of the challenge strain log count 
was carried out on the 7th day post-challenge. Correla-
tions were drawn between the bacterial counts and the 
high SIgA titers observed in Group C via oral admin-
istration (Figure  4A). The splenic log count was sig-
nificantly reduced in the adjuvanted group (Figure  5A). 
The increase in SIgA production induced by dmLT may 
have helped to neutralize the challenge bacteria and 
thus lessen splenic localization. As far as oral immuni-
zation is concerned, we speculate that the inclusion of 
dmLT improved the candidate vaccine strain by eliciting 
higher levels of intestinal SIgA production and, thereby 
may have prevented splenic colonization sooner than 
in the non-dmLT counterpart birds. Furthermore, all 
birds immunized via the intramuscular route showed a 
similar pattern of significantly reduced bacterial counts, 
irrespective of adjuvant inclusion (Figure  5B). The ceca 
of immunized birds were also significantly protected 
relative to those of control non-immunized groups 
(P  ≤  0.05). The overall organ bacterial counts were 
lower on the 14th day post-challenge than on the 7th day 
(Figures  5C  and D). Furthermore, the number of birds 
negative for the challenge strain was higher on the 14th 
day post-challenge (Table 4).
Our data demonstrated that JOL1641 could signifi-
cantly protect immunized birds from virulent wild-type 
challenge. The inclusion of adjuvant dmLT in the secre-
tions of JOL1641 strain increased SIgA production in 
the intestines of immunized birds. These increased SIgA 
levels may correlate with better splenic protection during 
Table 4 Isolation of challenge strain from internal organs of birds
a Number of organs positive of wild type SE/total number of organs examined.
Group Constructed strain Route Day post challenge Organa
Liver Spleen Caecum
A PBS control PBS 7 10/10 10/10 10/10
B JOL1087 Oral 7 10/10 10/10 10/10
Intramuscular 7 8/10 8/10 10/10
C JOL1641 Oral 7 8/10 8/10 10/10
Intramuscular 7 5/10 5/10 6/10
B JOL1087 Oral 14 3/10 5/10 5/10
Intramuscular 14 6/10 6/10 6/10
C JOL1641 Oral 14 5/10 5/10 5/10
Intramuscular 14 6/10 4/10 6/10
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early infection. In conclusion, this study reports a unique 
vaccine development strategy involving a live attenuated 
vaccine and an intrinsically incorporated mucosal adju-
vant. We also provided compelling data that this novel 
strain could be a new tool for poultry anti-Salmonella 
Enteritidis vaccination, especially as a means to boost 
the humoral immune response required for neutraliza-
tion during the early phases of invading Salmonellae 
infection.
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